We investigated the in vivo efficacy of tigecycline, a new glycylcycline (a tetracycline derivative), in the management of methicillin-resistant Staphylococcus aureus (MRSA)-infected experimental surgical wounds in rats. The main outcome measures were quantitative bacterial culture, histological examination and immunohistochemical expression of matrix metalloproteinase-9 (MMP-9) and collagen IV.
Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproteinase-9 modulation / Simonetti, O; Cirioni, O; Lucarini, G; Orlando, F; Ghiselli, R; Silvestri, C; Brescini, L; Rocchi, M; Provinciali, M; Guerrieri, M; Di Primio, R; Giacometti, A; Offidani, A. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 1460-2091. - ELETTRONICO. - 67:1(2012), pp. 191-201. [10.1093/jac/dkr440]
Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproteinase-9 modulation
Simonetti O;Cirioni O;Lucarini G;Ghiselli R;Silvestri C;Brescini L;Guerrieri M;Di Primio R;Giacometti A;Offidani A
2012-01-01
Abstract
We investigated the in vivo efficacy of tigecycline, a new glycylcycline (a tetracycline derivative), in the management of methicillin-resistant Staphylococcus aureus (MRSA)-infected experimental surgical wounds in rats. The main outcome measures were quantitative bacterial culture, histological examination and immunohistochemical expression of matrix metalloproteinase-9 (MMP-9) and collagen IV.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
